US Patent 7494660 HCV NS3-NS4A protease resistance mutants
Patent 7494660 was granted and assigned to Vertex Pharmaceuticals on February, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 17 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Chao Lin0
Kai Lin0
Edits on 15 Sep, 2023
Golden AI
Edits made to:
Article (+203 characters)
Article
Patent abstract
The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07494660 HCV NS3-NS4A protease resistance mutants US Patent 7494660 HCV NS3-NS4A protease resistance mutants
Infobox
Patent Number
074946600
Patent Number
74946600
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
074946600
Date of Patent
February 24, 2009
0Patent Application Number
109745580
Date Filed
October 27, 2004
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 1 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07494660 HCV NS3-NS4A protease resistance mutants
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07494660
Date of patent
February 24, 2009
Patent application number
10974558
Date Filed
October 27, 2004
Patent primary examiner
Find more entities like US Patent 7494660 HCV NS3-NS4A protease resistance mutants
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.